PACIRA BIOSCIENCES, INC. Proceeds from Secured Notes Payable
PACIRA BIOSCIENCES, INC. (PCRX) reported Proceeds from Secured Notes Payable of $56.25 million for the 12-month period ending 2010-12-31, per its 10-K filed 2013-03-07.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromSecuredNotesPayable · last filed 2013-03-07
- PACIRA BIOSCIENCES, INC. proceeds from secured notes payable for the quarter ending 2010-12-31 was $37.50M.
- PACIRA BIOSCIENCES, INC. proceeds from secured notes payable for the quarter ending 2010-09-30 was $4.69M.
- PACIRA BIOSCIENCES, INC. proceeds from secured notes payable for fiscal 2010 was $56.25M, a 429.41% increase from fiscal 2009.
- PACIRA BIOSCIENCES, INC. proceeds from secured notes payable for fiscal 2009 was $10.63M.
| Period end | Proceeds from Secured Notes Payable 3 month | Proceeds from Secured Notes Payable 6 month | Proceeds from Secured Notes Payable 9 month | Proceeds from Secured Notes Payable 12 month |
|---|---|---|---|---|
| 2010-12-31 | $37.50M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-07 | $42.19M derived: sum of 2 quarters · filed 2013-03-07 | $56.25M 10-K · filed 2013-03-07 | |
| 2010-09-30 | $4.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-31 | $18.75M 10-Q · filed 2011-10-31 | ||
| 2010-06-30 | $14.06M 10-Q · filed 2011-08-11 | |||
| 2009-12-31 | $10.63M 10-K · filed 2012-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |